Nasdaq4d
Check Out What Whales Are Doing With CRSP
High-rolling investors have positioned themselves bullish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today ...
Nasdaq9d
CRSP February 14th Options Begin Trading
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Brokers Issue Forecasts for CRSP FY2024 Earnings
Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...
Nasdaq9d
CRSP Factor-Based Stock Analysis - Benjamin Graham
Below is Validea's guru fundamental report for CRISPR THERAPEUTICS AG (CRSP). Of the 22 guru strategies we follow, CRSP rates highest using our Value Investor model based on the published strategy ...
Nasdaq10d
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36 ... Meanwhile, the Dow lost 0.07%, and the Nasdaq, a tech-heavy index, lost 0.9%.
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $85.00 at Bank of America
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...
Nordea Investment Management AB Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Nordea Investment Management AB grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.4% in the ...
1 growth stock that could soar 105%, according to Wall Street experts
This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...
Nasdaq11d
Crispr Therapeutics call volume above normal and directionally bullish
Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points to 57.05%. Jan-26 100 calls and Jan-26 60 calls are ...
Brookline Capital Management Forecasts CRSP FY2029 Earnings
Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...
Nasdaq22d
Interesting CRSP Put And Call Options For February 2025
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading this week, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...